PA
CORT icon

Parallel Advisors’s Corcept Therapeutics CORT Stock Holding History

Parallel Advisors’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$345M Sell
3,962,177
-15,227
-0.4% -$919K 5.25% 2
2026
Q1 		$160M Buy
3,977,404
+98,263
+3% +$3.67M 2.88% 5
2025
Q4 		$135M Buy
3,879,141
+7,689
+0.2% +$604K 2.47% 6
2025
Q3 		$322M Buy
3,871,452
+329
+0% +$23.8K 5.89% 3
2025
Q2 		$284M Sell
3,871,123
-101,293
-3% -$7.34M 5.68% 3
2025
Q1 		$220M Buy
3,972,416
+142,784
+4% +$8.69M 4.95% 3
2024
Q4 		$193M Buy
3,829,632
+15,908
+0.4% +$834K 4.34% 4
2024
Q3 		$176M Sell
3,813,724
-2,036
-0.1% -$72.3K 4.15% 4
2024
Q2 		$124M Buy
3,815,760
+83
+0% +$2.27K 3.18% 5
2024
Q1 		$96.1M Buy
3,815,677
+47,432
+1% +$1.12M 2.6% 5
2023
Q4 		$122M Buy
3,768,245
+44,762
+1% +$1.23M 3.63% 4
2023
Q3 		$101M Sell
3,723,483
-3,082
-0.1% -$89.2K 3.38% 3
2023
Q2 		$82.9M Buy
3,726,565
+1,992
+0.1% +$45.8K 2.67% 4
2023
Q1 		$80.7M Sell
3,724,573
-91
-0% -$2K 2.72% 4
2022
Q4 		$75.6M Sell
3,724,664
-44,791
-1% -$1.12M 3.28% 5
2022
Q3 		$96.6M Buy
3,769,455
+1,051,127
+39% +$28.1M 4.45% 3
2022
Q2 		$64.6M Buy
2,718,328
+774,009
+40% +$16.9M 2.97% 5
2022
Q1 		$47M Buy
1,944,319
+140,937
+8% +$3M 1.87% 9
2021
Q4 		$35.7M Buy
1,803,382
+76,474
+4% +$1.55M 1.33% 11
2021
Q3 		$34M Buy
1,726,908
+52,551
+3% +$1.1M 1.37% 10
2021
Q2 		$36.8M Buy
1,674,357
+110,383
+7% +$2.46M 1.56% 11
2021
Q1 		$37.2M Buy
1,563,974
+15,358
+1% +$410K 1.76% 10
2020
Q4 		$40.5M Buy
1,548,616
+253,712
+20% +$5.35M 2.2% 7
2020
Q3 		$22.5M Sell
1,294,904
-109,541
-8% -$1.75M 1.39% 15
2020
Q2 		$23.6M Sell
1,404,445
-1,450
-0.1% -$20.4K 1.54% 12
2020
Q1 		$16.7M Hold
1,405,895
– – 1.35% 13
2019
Q4 		$17M Buy
1,405,895
+128,044
+10% +$1.78M 1.28% 14
2019
Q3 		$18.1M Buy
1,277,851
+1,275,251
+49,048% +$15.7M 1.55% 11
2019
Q2 		$29K Buy
+2,600
New +$29K ﹤0.01% 1110

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Parallel Advisors's CORT Position: Q2 2026 in Review

Parallel Advisors reduced its Corcept Therapeutics (CORT) stake by 0.38% in Q2 2026, selling an estimated $919K and leaving 3,962,177 shares worth $345M. The position accounts for 5.25% of the portfolio, ranked #2.

Parallel Advisors first reported a position in CORT in Q2 2019 and has held it in 29 quarters since. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Parallel Advisors held 3,962,177 shares of Corcept Therapeutics worth $345M as of Q2 2026.
  • Parallel Advisors sold 15,227 Corcept Therapeutics shares in Q2 2026, an estimated $919K.
  • Corcept Therapeutics made up 5.25% of Parallel Advisors's portfolio in Q2 2026, its #2 holding.
  • Parallel Advisors first reported a position in Corcept Therapeutics in Q2 2019 and has held it in 29 quarters since.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.